From June 25th to 28th, the "2023 Pharmaceutical and Healthcare Industry Symbiosis Conference," hosted by MinEnet, was grandly held in Huzhou, Zhejiang! Themed "Resilience, New Beginnings," the conference foreshadows the relentless and enterprising spirit of China's pharmaceutical and healthcare industry, as it strives to overcome obstacles and embrace change.

With the opening of the conference, MinEnet released the 2023 China Pharmaceutical Industry Top 100 series of lists. Fushine Pharmaceuticals, relying on its outstanding innovation capabilities, solid product quality and stable market influence, once again topped the "China Chemical Pharmaceutical Enterprises TOP100" list!

In 2023, the years are passing by, and the years are gilded
Fushine people are indomitable and become steel through repeated tempering

2023 is a year of perseverance and continuous struggle, a year of striding forward with confidence and forging ahead, a year of remaining true to our original aspiration and taking firm steps.

“Resilience and a New Era”

Every June-July, the MISH Conference (Pharmaceutical and Healthcare Industry Symbiosis Conference) arrives as scheduled. This is a well-known annual event in the pharmaceutical and healthcare industry, and it is also a top conference to commend benchmark companies and interpret the future of the pharmaceutical industry!
Relying on the MinEnet database, which integrates pharmaceutical and health industry research, hospital market research, retail market research, commercial channel research, and Internet online pharmaceutical and health information services, MISI mainly judges based on the innovation driving force and professional promotion ability of industrial enterprises. Therefore, MISI's China Pharmaceutical Industry Top 100 Enterprises List is one of the brand lists widely recognized by the domestic pharmaceutical industry. The companies on the list represent their competitiveness, influence and development level in the industry.

Maintain stability, increase efficiency, innovate and seek change

In 2023, Fushine Pharmaceuticals will continue to deepen its pharmaceutical business, focusing on cost reduction and efficiency improvement. By promoting process optimization and technological innovation, it will promote product registration and certification in regulated markets both domestically and internationally, continuously enhancing its market competitiveness and consolidating its existing dominant position in the pharmaceutical segment. The pharmaceutical manufacturing business achieved sales revenue of RMB 1.321 billion.

Specifically, the company has achieved the following results in the research and development of its pharmaceutical manufacturing business: First, it successfully developed tazobactam using a triazole process, which can effectively improve the inherent safety of product production, improve drug quality, and reduce production costs. Secondly, the company actively expanded downstream, improved its product structure, and developed the sterile lyophilized API tazobactam sodium. Tazobactam using a triazole process and the sterile lyophilized API tazobactam sodium have both obtained the "Notice of Approval of Application for Marketing of Chemical APIs" issued by the State Food and Drug Administration. Finally, Xiangtai Scientific's tazobactam API, production workshop, and production line passed the pharmaceutical GMP compliance inspection. Xiangtai Scientific's sitafloxacin and paroxetine hydrochloride have obtained the "Notice of Approval of Application for Marketing of Chemical APIs" issued by the State Food and Drug Administration.

In the future, the company will continue to focus on pharmaceuticals as its main business, adhere to R&D-driven development, and deeply implement the mission of "making medicines with care and protecting health". It will strive towards the vision of becoming a world-renowned pharmaceutical company and is determined to make greater contributions to human health.